Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q1 2020

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inari Medical reports robust Q4 earnings and eyes international expansion

Inari Medical's Q4 2022 earnings call highlighted strong revenue growth, operational challenges, and strategic opportunities for market expansion and product innovation.
The company's focus on patient outcomes, superior product performance, and international growth positions it for continued success in 2023 and beyond.
Efforts to optimize gross margins, manage operating expenses, and drive market adoption present key areas for Inari's future financial performance and profitability.
With a clear revenue guidance for 2023 and a commitment to sustained operating profitability, Inari Medical demonstrates a strategic roadmap for sustainable growth.

Inari Medical reports robust Q1 earnings, eyes sustained profitability

Inari Medical's Q1 earnings call highlighted strong financial performance, growth strategies, and product innovations. Challenges include competitive dynamics and assessing seasonality trends. The company is well-positioned for sustained growth and market expansion.

Inari Medical reports record revenue and eyes Asian market expansion

Inari Medical's Q2 2023 performance reflects robust financial growth, international expansion, and a strategic focus on addressing unmet needs in the CVD market.
With a strong product portfolio, sustained profitability, and market development initiatives, Inari Medical is well-equipped to capitalize on growth opportunities and drive innovation.
Challenges in market entry, product redesign timelines, and regulatory approvals are being navigated as the company aims for sustained growth and market leadership in the medical device sector.

Inari Medical reports robust Q3 earnings, acquires LimFlow for growth

Inari Medical's Q3 performance reflects strong financial growth, operational improvements, and strategic acquisitions driving future prospects.
While challenges like declining margins and delayed profit targets exist, opportunities in new markets, product pricing, and synergies offer avenues for sustained growth.
The LimFlow acquisition positions Inari well in the CLTI market, with a focus on revenue growth, operational efficiency, and market expansion.
Overall, Inari's confidence in its core business and strategic moves like the LimFlow acquisition signal a positive trajectory and growth outlook.

Inari Medical reports record revenue, eyes sustained profitability amid challenges

Inari Medical's Q4 2023 performance showcased strong revenue growth, operational progress, and a strategic focus on market leadership and patient care.
While facing challenges such as regulatory scrutiny and increased operating expenses, the company remains optimistic about revenue growth and sustained profitability.
Opportunities lie in diversified revenue streams, international expansion, and product portfolio enhancements, positioning Inari for continued growth and market leadership.
Overall, Inari Medical's strategic initiatives and financial performance indicate a resilient and growth-oriented trajectory in the medical device industry.

Inari Medical reports record Q1 revenue, raises full-year guidance

Inari Medical's Q1 performance reflects robust revenue growth, strategic investments, and international expansion, positioning the company for sustained profitability and market leadership.
While facing challenges in competition and market dynamics, Inari's strengths in innovation, global performance, and product development offer avenues for growth and differentiation.
The company's focus on operational efficiency, strategic investments, and product enhancements align with opportunities in expanding toolkits, new therapies, and market presence.

Inari Medical reports record revenue, eyes sustained profitability and global expansion

Inari Medical's Q2 2024 performance reflects strong revenue growth but with operating losses, signaling a need for cost management strategies.
The company's strategic strengths lie in sustained profitability projections, successful business integrations, and expansion into key international markets.
Challenges include leadership transition risks, operational hurdles in new markets, and the need to meet high market expectations with upcoming data releases.
Opportunities for Inari include optimizing costs, leveraging growth in China and Japan, capitalizing on new product adoption, and driving further market expansion.

Inari Medical reports record revenue and eyes global expansion

Inari Medical's Q3 performance reflects robust revenue growth and strategic focus on expanding therapies globally.
The company's strengths lie in revised revenue guidance, upcoming profitability, and promising study outcomes.
Challenges include managing expenses, reducing losses, and sustaining high margins amidst market competition.
Opportunities abound in driving growth, capitalizing on new therapies, and expanding market presence internationally.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.

IRVINE, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Mr. Dana G. Mead, Jr. to its board of directors. Mr. Mead will serve as a member of the Compensation Committee of the board.

Inari Medical Appoints Dana G. Mead, Jr. to Board of Directors

Fulgent Genetics

Teladoc

It doesn't take a lot of upfront cash to add one of these stocks to your portfolio.

3 Top Healthcare Stocks You Can Buy for $100 or Less

American Airlines

Beyond Meat

Sabre

The Dow rose about 210 points, the S&P 500 rebounded by 0.6%, and the Nasdaq added another 0.6%. Find opportunities in today's market with the best short plays from Q.ai's deep learning algorithms.

American Airlines Group Inc Ranked Among Today's Top Shorts As COVID-19 Concerns Continue To Rise

Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock?

Why Is Inari Medical, Inc. (NARI) Up 8.8% Since Last Earnings Report?

Hims & Hers Health

Renalytix AI plc

All three are rapidly expanding into their own corners of America's $4 trillion per year healthcare sector.

3 High-Growth Healthcare Stocks to Buy in September

Redfin

There's a stock on this list analysts think can climb by around 47%, as soon as more investors come around to their way of seeing things.

3 High-Growth Stocks That Could Soar by 30% or Better According to Wall Street

Even the median estimate would be a 70% gain.

Wall Street Thinks This Healthcare Stock Could Double Your Money in the Next Year

The stock price is collapsing as a result.

This Healthcare Company Just Shocked Its Investors

Inari Medical Inc's (NASDAQ: NARI) Q2 revenue was $63.5 million, more than doubled from $25.4 million in Q2 FY20, beating the consensus of $59.6 million. The growth was driven by continued U.S. commercial expansion and new product introductions.

Inari Medical Plunged 15% After Mixed Q2 Earnings, Lifting FY21 Sales Guidance

Dollars outpaced procedures in the second quarter.

Why Shares of Inari Medical Are Falling Today

Inari Medical's (NARI) second-quarter 2021 results benefit from significant revenue growth and gross margin expansion.

Inari Medical (NARI) Q2 Earnings Lag, Revenues Top Estimates

Inari Medical, Inc. (NARI) CEO Bill Hoffman on Q2 2021 Results - Earnings Call Transcript

Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of -22.22% and 5.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Inari Medical, Inc. (NARI) Misses Q2 Earnings Estimates

Shares of Inari Medical (NASDAQ:NARI) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 143.75% year over year to $0.07, which missed the estimate of $0.08.

Inari Medical: Q2 Earnings Insights

IRVINE, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2021.

Inari Medical Reports Second Quarter 2021 Financial Results

3 Things I'm Looking For in Inari Medical's Earnings

Novavax

Pfizer

Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.

3 COVID Stocks That Could Soar Higher

Inari Medical, Inc. (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inari Medical, Inc. (NARI) Earnings Expected to Grow: Should You Buy?

Cinemark Holdings

Las Vegas Sands

Roku

The Dow Jones gained 94 points, or 0.4%, the S&P 500 added 0.2%, and the Nasdaq rose 0.1%. Find opportunities with today's best short plays from Q.ai's deep learning algorithms.

Cinemark Holdings Inc Ranked Among Today's Top Shorts

IRVINE, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that its management team will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 10:30 a.m. Eastern Time.

Inari Medical to Present at the Canaccord Genuity 41st Annual Growth Conference

Amazon

The overall market might be expensive, but these stocks aren't.

2 Best Buys of the Nasdaq Right Now

IRVINE, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release its second quarter financial results on Tuesday, August 10, 2021. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce Second Quarter 2021 Financial Results

IRVINE, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Ms. Rebecca Chambers to its board of directors. Ms. Chambers also will serve as a member of the Audit Committee. Ms. Chambers, currently Chief Financial Officer of Outset Medical, Inc., brings more than a decade of healthcare leadership experience. Over the course of her career, Ms. Chambers has led numerous financial functions as well as served in leadership roles in investor relations for publicly traded companies in the healthcare space.

Inari Medical Appoints Outset Medical Executive Rebecca Chambers to Board of Directors

IRVINE, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced strongly positive interim results of the first 250 deep vein thrombosis (“DVT”) patients enrolled in the ClotTriever Outcomes Registry (“CLOUT”). This latest data showed that ClotTriever removed 100% of the blood clots in the majority of DVT patients without the need for thrombolytic drugs in short single-session procedures. The late-breaking data was presented virtually at NCVH 2021 by principal investigator, Robert Beasley, MD, an interventional radiologist at Palm Vascular Center in Miami, FL.

Inari Medical Announces Late-Breaking CLOUT Registry Data Demonstrating Long-Term Benefits of Lytic-Free Single-Session Near Bloodless Thrombectomy in First 250 Real-World DVT Patients

Flawless execution of management's plan could lead to big gains for the stock in the years ahead.

News for Inari Medical Stock (NARI)